|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shimozawa N and Hanazaki K: Longterm
prognosis after hepatic resection for small hepatocellular
carcinoma. J Am Coll Surg. 198:356–365. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Verhoef C, de Man RA, Zondervan PE,
Eijkemans MJ, Tilanus HW and Ijzermans JN: Good outcomes after
resection of large hepatocellular carcinoma in the non-cirrhotic
liver. Dig Surg. 21:380–386. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lang H, Sotiropoulos GC, Brokalaki EI,
Schmitz KJ, Bertona C, Meyer G, Frilling A, Paul A, Malagó M and
Broelsch CE: Survival and recurrence rates after resection for
hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg.
205:27–36. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hendrich B, Abbott C, Mcqueen H, Chambers
D, Cross S and Bird A: Genomic structure and chromosomal mapping of
the murine and human Mbd1, Mbd2, Mbd3 and Mbd4 genes. Mamm Genome.
10:906–912. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xiong Y, Dowdy SC, Eberhardt NL, Podratz
KC and Jiang SW: hMLH1 promoter methylation and silencing in
primary endometrial cancers are associated with specific
alterations in MBDs occupancy and histone modifications. Gynecol
Oncol. 103:321–328. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Auriol E, Billard LM, Magdinier F and
Dante R: Specific binding of the methyl binding domain protein 2 at
the BRCA1-NBR2 locus. Nucleic Acids Res. 33:4243–4254. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mian OY, Wang SZ, Zhu SZ, Gnanapragasam
MN, Graham L, Bear HD and Ginder GD: Methyl-binding domain protein
2-dependent proliferation and survival of breast cancer cells. Mol
Cancer Res. 9:1152–1162. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Campbell PM, Bovenzi V and Szyf M:
Methylated DNA-binding protein 2 antisense inhibitors suppress
tumourigenesis of human cancer cell lines in vitro and in vivo.
Carcinogenesis. 25:499–507. 2004. View Article : Google Scholar
|
|
10
|
Bakker J, Lin X and Nelson WG: Methyl-CpG
binding domain protein 2 represses transcription from
hypermethylated pi-class glutathione S-transferase gene promoters
in hepatocellular carcinoma cells. J Biol Chem. 277:22573–22580.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stefanska B, Suderman M, Machnes Z,
Bhattacharyya B, Hallett M and Szyf M: Transcription onset of genes
critical in liver carcinogenesis is epigenetically regulated by
methylated DNA-binding protein MBD2. Carcinogenesis. 34:2738–2749.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ballestar E, Yusufzai TM and Wolffe AP:
Effects of Rett syndrome mutations of the methyl-CpG binding domain
of the transcriptional repressor MeCP2 on selectivity for
association with methylated DNA. Biochemistry. 39:7100–7106. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wade PA: Methyl CpG-binding proteins and
transcriptional repression. Bioessays. 23:1131–1137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Barr H, Hermann A, Berger J, Tsai HH, Adie
K, Prokhortchouk A, Hendrich B and Bird A: Mbd2 contributes to DNA
methylation-directed repression of the Xist gene. Mol Cell Biol.
27:3750–3757. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hendrich B and Bird A: Identification and
characterization of a family of mammalian methyl-CpG binding
proteins. Mol Cell Biol. 18:6538–6547. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shukeir N, Pakneshan P, Chen G, Szyf M and
Rabbani SA: Alteration of the methylation status of tumor-promoting
genes decreases prostate cancer cell invasiveness and tumorigenesis
in vitro and in vivo. Cancer Res. 66:9202–9210. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stefanska B, Huang J, Bhattacharyya B,
Suderman M, Hallett M, Han ZG and Szyf M: Definition of the
landscape of promoter DNA hypomethylation in liver cancer. Cancer
Res. 71:5891–5903. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pakneshan P, Szyf M, Farias-Eisner R and
Rabbani SA: Reversal of the hypomethylation status of urokinase
(uPA) promoter blocks breast cancer growth and metastasis. J Biol
Chem. 279:31735–31744. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Martin V, Jørgensen HF, Chaubert AS,
Berger J, Barr H, Shaw P, Bird A and Chaubert P: MBD2-mediated
transcriptional repression of the p14ARF tumor suppressor gene in
human colon cancer cells. Pathobiology. 75:281–287. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Slack A, Bovenzi V, Bigey P, Ivanov MA,
Ramchandani S, Bhattacharya S, tenOever B, Lamrihi B, Scherman D
and Szyf M: Antisense MBD2 gene therapy inhibits tumorigenesis. J
Gene Med. 4:381–389. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ivanov MA, Lamrihi B, Szyf M, Scherman D
and Bigey P: Enhanced antitumor activity of a combination of
MBD2-antisense electrotransfer gene therapy and bleomycin
electrochemotherapy. J Gene Med. 5:893–899. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu XY, Tang SH, Wu SL, Luo YH, Cao MR,
Zhou HK, Jiang XW, Shu JC, Bie CQ, Huang SM, et al: Epigenetic
modulation of insulin-like growth factor-II overexpression by
hepatitis B virus X protein in hepatocellular carcinoma. Am J
Cancer Res. 5:956–978. 2015.PubMed/NCBI
|
|
23
|
Ataide EC, Boin IF, Almeida JR,
Sevá-Pereira T, Stucchi RS, Cardoso AR, Caruy CA and Escanhoela CA:
Prognostic factors for hepatocellular carcinoma recurrence:
Experience with 83 liver transplantation patients. Transplant Proc.
43:1362–1364. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nobuoka D, Kato Y, Gotohda N, Takahashi S,
Nakagohri T, Konishi M, Kinoshita T and Nakatsura T: Postoperative
serum alpha-fetoprotein level is a useful predictor of recurrence
after hepatectomy for hepatocellular carcinoma. Oncol Rep.
24:521–528. 2010.PubMed/NCBI
|
|
25
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bruix J and Sherman M; Practice Guidelines
Committee American Association for the Study of Liver Diseases:
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tandon P and Garcia-Tsao G: Prognostic
indicators in hepatocellular carcinoma: A systematic review of 72
studies. Liver Int. 29:502–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
van Malenstein H, van Pelt J and Verslype
C: Molecular classification of hepatocellular carcinoma anno 2011.
Eur J Cancer. 47:1789–1797. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sumie S, Kuromatsu R, Okuda K, Ando E,
Takata A, Fukushima N, Watanabe Y, Kojiro M and Sata M:
Microvascular invasion in patients with hepatocellular carcinoma
and its predictable clini-copathological factors. Ann Surg Oncol.
15:1375–1382. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Eguchi S, Takatsuki M, Hidaka M, Soyama A,
Tomonaga T, Muraoka I and Kanematsu T: Predictor for histological
micro-vascular invasion of hepatocellular carcinoma: A lesson from
229 consecutive cases of curative liver resection. World J Surg.
34:1034–1038. 2010. View Article : Google Scholar : PubMed/NCBI
|
